Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Array CGH identifies copy number changes in 11% of 520 MDS patients with normal karyotype and uncovers prognostically relevant deletions

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Greenberg P, Cox C, Le Beau MM, Fenaux P, Morel P, Sanz G et al. International Scoring System for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079–2088.

    CAS  PubMed  Google Scholar 

  2. Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F et al. Revised International Prognostic Scoring System (IPSS-R) for myelodysplastic syndromes. Blood 2012; 120: 2454–2465.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Haase D . Cytogenetic features in myelodysplastic syndromes. Ann Hematol 2008; 87: 515–526.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Haferlach T, Nagata Y, Grossmann V, Okuno Y, Bacher U, Nagae G et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 2014; 28: 241–247.

    Article  CAS  PubMed  Google Scholar 

  5. Löffler H, Rastetter J, Haferlach T . Atlas of Clinical Hematology, 6th edn Springer: Heidelberg, 2010.

    Google Scholar 

  6. Brunning RD, Bennett JM, Flandrin G, Matutes E, Head D, Vardiman J et alMyelodysplastic syndromes In Jaffe ES, Harris N, Stein H, Vardiman J (eds). World Health Organization of Tumors, Pathology & Genetics, Tumors of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon, 2001; pp 61–73.

    Google Scholar 

  7. Brunning RD, Orazi A, Germing U, Le Beau MM, Porwit A, Baumann I et al. Myelodysplastic syndromes. In: Swerdlow S, Campo E, Lee Harris N, Jaffe ES, Pileri SA, Stein H et al. (eds). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edn IARC Press: Lyon, 2008; pp 87–93.

    Google Scholar 

  8. Wiktor A, Rybicki BA, Piao ZS, Shurafa M, Barthel B, Maeda K et al. Clinical significance of Y chromosome loss in hematologic disease. Genes Chromosomes Cancer 2000; 27: 11–16.

    Article  CAS  PubMed  Google Scholar 

  9. McNerney ME, Brown CD, Wang X, Bartom ET, Karmakar S, Bandlamudi C et al. CUX1 is a haploinsufficient tumor suppressor gene on chromosome 7 frequently inactivated in acute myeloid leukemia. Blood 2013; 121: 975–983.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Kolquist KA, Schultz RA, Furrow A, Brown TC, Han JY, Campbell LJ et al. Microarray-based comparative genomic hybridization of cancer targets reveals novel, recurrent genetic aberrations in the myelodysplastic syndromes. Cancer Genet 2011; 204: 603–628.

    Article  CAS  PubMed  Google Scholar 

  11. Sato Y, Suto Y, Pietenpol J, Golub TR, Gilliland DG, Davis EM et al. TEL and KIP1 define the smallest region of deletions on 12p13 in hematopoietic malignancies. Blood 1995; 86: 1525–1533.

    CAS  PubMed  Google Scholar 

  12. Kon A, Shih LY, Minamino M, Sanada M, Shiraishi Y, Nagata Y et al. Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms. Nat Genet 2013; 45: 1232–1237.

    Article  CAS  PubMed  Google Scholar 

  13. Mohamedali A, Gaken J, Twine NA, Ingram W, Westwood N, Lea NC et al. Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes. Blood 2007; 110: 3365–3373.

    Article  CAS  PubMed  Google Scholar 

  14. Bacher U, Weissmann S, Kohlmann A, Schindela S, Alpermann T, Schnittger S et al. TET2 deletions are a recurrent but rare phenomenon in myeloid malignancies and are frequently accompanied by TET2 mutations on the remaining allele. Br J Haematol 2012; 156: 67–75.

    Article  PubMed  Google Scholar 

  15. Tiu RV, Gondek LP, O'Keefe CL, Elson P, Huh J, Mohamedali A et al. Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies. Blood 2011; 117: 4552–4560.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to C Haferlach.

Ethics declarations

Competing interests

WK, SS, TH and CH declare part ownership of the MLL Munich Leukemia Laboratory. SV, MZ, MS and JH are employed by the MLL Munich Leukemia Laboratory. All other authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Volkert, S., Haferlach, T., Holzwarth, J. et al. Array CGH identifies copy number changes in 11% of 520 MDS patients with normal karyotype and uncovers prognostically relevant deletions. Leukemia 30, 259–261 (2016). https://doi.org/10.1038/leu.2015.257

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2015.257

This article is cited by

Search

Quick links